Share

TransMedics Group Inc (TMDX.NASDAQ) AI OPINIONS & ADVISOR ANALYSIS

Read and compare the 12 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 5 June 2026Deep analysis 5 June 2026

Publisher

Russlan Ramdowar

25 min readAudit All Past Forecasts

12 AI Advisor Reports

Select an advisor report.

SynthesizerCombines all advisor views

Synthesis of 12 independent opinions

Diversity of FrameworksDifferent investing styles

AI Thinker

Gemini 3.1 Pro

Elon Musk AI

The Visionary Framework

Model rating

Strong Buy

5-Year Return Est.

+304.6%

TMDX.NASDAQ does not currently pay dividends

1. Investment Thesis — Base Case

TransMedics is a textbook Paradigm Shifter operating in the steep acceleration phase of its S-curve. The physics are undisputed: warm perfusion is biologically superior to cold ice storage. Wall Street has severely mispriced this asset due to global macro noise, handing visionary capital a monopoly growing at 37% for a meager 15 P/E.

The NOP aviation fleet acts as an impenetrable infrastructure moat.
DCD organ utilization provides a structural expansion to the TAM.
Cash burn is history; $151M TTM FCF proves escape velocity has been achieved.
Energy shocks present a near-term friction, but inelastic demand ensures pricing power protects margins.
At current valuations, the implied market capitalization fundamentally underestimates the global monopoly on biological transport.

Historical prices and published forecast

Observed price
Published advisor forecast

Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.

View chart values

Historical prices and published forecast — published chart values
Series	Date	Value (USD)
Observed price	2021-05-31	25.9
Observed price	2021-06-24	30.6
Observed price	2021-07-10	34.2
Observed price	2021-07-18	28.7
Observed price	2021-08-07	31.0
Observed price	2021-08-19	25.9
Observed price	2021-08-23	28.1
Observed price	2021-08-31	32.7
Observed price	2021-10-02	31.6
Observed price	2021-10-10	27.0
Observed price	2021-10-18	26.3
Observed price	2021-11-07	31.9
Observed price	2021-11-15	25.7
Observed price	2021-11-27	21.9
Observed price	2021-12-13	21.6
Observed price	2022-01-06	18.38
Observed price	2022-01-10	17.19
Observed price	2022-02-03	14.52
Observed price	2022-02-23	12.58
Observed price	2022-03-03	18.83
Observed price	2022-03-15	17.76
Observed price	2022-03-31	26.9
Observed price	2022-04-04	27.6
Observed price	2022-04-28	21.9
Observed price	2022-05-02	22.0
Observed price	2022-05-14	28.7
Observed price	2022-06-11	25.9
Observed price	2022-06-23	31.9
Observed price	2022-07-13	31.6
Observed price	2022-07-21	35.2
Observed price	2022-07-25	34.5
Observed price	2022-08-06	47.9
Observed price	2022-08-22	47.1
Observed price	2022-09-11	55.0
Observed price	2022-09-19	50.5
Observed price	2022-09-27	40.1
Observed price	2022-10-17	40.7
Observed price	2022-11-06	57.2
Observed price	2022-11-18	57.0
Observed price	2022-12-04	62.7
Observed price	2022-12-12	59.5
Observed price	2023-01-05	54.6
Observed price	2023-01-09	53.6
Observed price	2023-02-02	67.9
Observed price	2023-02-10	63.7
Observed price	2023-03-02	80.0
Observed price	2023-03-06	80.9
Observed price	2023-03-10	71.5
Observed price	2023-04-15	67.4
Observed price	2023-04-23	86.9
Observed price	2023-05-01	77.8
Observed price	2023-05-25	71.3
Observed price	2023-05-29	71.9
Observed price	2023-06-14	81.8
Observed price	2023-06-26	80.0
Observed price	2023-07-16	93.2
Observed price	2023-08-01	93.9
Observed price	2023-08-17	63.0
Observed price	2023-09-02	67.9
Observed price	2023-09-14	59.1
Observed price	2023-09-18	58.9
Observed price	2023-10-12	44.1
Observed price	2023-10-28	37.6
Observed price	2023-11-09	58.3
Observed price	2023-11-13	59.6
Observed price	2023-12-07	75.1
Observed price	2023-12-11	71.9
Observed price	2023-12-27	80.5
Observed price	2024-01-16	79.3
Observed price	2024-02-01	88.5
Observed price	2024-02-17	89.6
Observed price	2024-02-25	79.5
Observed price	2024-03-04	87.0
Observed price	2024-03-24	71.0
Observed price	2024-04-01	73.4
Observed price	2024-04-09	93.2
Observed price	2024-04-29	97.3
Observed price	2024-05-19	138
Observed price	2024-06-04	134
Observed price	2024-06-20	144
Observed price	2024-07-06	151
Observed price	2024-07-10	139
Observed price	2024-07-30	138
Observed price	2024-08-15	170
Observed price	2024-08-27	176
Observed price	2024-09-08	140
Observed price	2024-09-20	165
Observed price	2024-10-06	136
Observed price	2024-10-14	134
Observed price	2024-10-30	81.9
Observed price	2024-11-11	89.1
Observed price	2024-12-05	66.3
Observed price	2024-12-09	69.8
Observed price	2024-12-29	59.9
Observed price	2025-01-06	75.6
Observed price	2025-01-18	57.1
Observed price	2025-02-11	68.1
Observed price	2025-02-19	79.4
Observed price	2025-03-07	67.5
Observed price	2025-03-23	70.7
Observed price	2025-03-31	67.3
Observed price	2025-04-24	94.2
Observed price	2025-05-02	90.0
Observed price	2025-05-22	123
Observed price	2025-06-11	143
Observed price	2025-06-19	124
Observed price	2025-06-27	131
Observed price	2025-07-17	113
Observed price	2025-07-21	104
Observed price	2025-08-14	130
Observed price	2025-08-18	126
Observed price	2025-09-07	105
Observed price	2025-09-19	122
Observed price	2025-10-09	113
Observed price	2025-10-13	112
Observed price	2025-10-29	134
Observed price	2025-11-14	115
Observed price	2025-11-30	149
Observed price	2025-12-08	137
Observed price	2026-01-01	122
Observed price	2026-01-05	126
Observed price	2026-01-17	143
Observed price	2026-02-10	139
Observed price	2026-02-14	131
Observed price	2026-03-02	147
Observed price	2026-03-26	102
Observed price	2026-03-30	94.3
Observed price	2026-04-15	116
Observed price	2026-04-27	108
Observed price	2026-05-13	64.2
Observed price	2026-05-29	67.2
Observed price	2026-06-18	78.8
Observed price	2026-06-30	66.4
Observed price	2026-07-16	76.0
Observed price	2026-07-24	72.3
Observed price	2026-08-13	89.6
Observed price	2026-08-21	94.8
Observed price	2026-09-02	84.3
Observed price	2026-09-22	88.1
Observed price	2026-09-24	83.9
Observed price	2026-09-25	85.3
Published advisor forecast	2026-06-04	71.4
Published advisor forecast	2026-09-04	84.2
Published advisor forecast	2026-12-04	94.3
Published advisor forecast	2027-03-04	88.7
Published advisor forecast	2027-06-04	96.6
Published advisor forecast	2027-09-04	110
Published advisor forecast	2027-12-04	127
Published advisor forecast	2028-03-04	137
Published advisor forecast	2028-06-04	144
Published advisor forecast	2028-09-04	132
Published advisor forecast	2028-12-04	147
Published advisor forecast	2029-03-04	164
Published advisor forecast	2029-06-04	176
Published advisor forecast	2029-09-04	192
Published advisor forecast	2029-12-04	203
Published advisor forecast	2030-03-04	223
Published advisor forecast	2030-06-04	212
Published advisor forecast	2030-09-04	229
Published advisor forecast	2030-12-04	252
Published advisor forecast	2031-03-04	267
Published advisor forecast	2031-06-04	289

2. Scenarios & Signals

Bull case

The Base Case accelerates as AI predictive diagnostics integrate into the OCS platform, raising the success probability of transplants to near 100%.

Xenotransplantation pioneers select TMDX as their exclusive logistics partner.
International rollout in Europe and Asia scales rapidly without massive Capex, leveraging local operators.
Valuation multiple expands to 45x as Wall Street re-classifies TMDX as essential life-saving infrastructure.

Bear case

The Base Case falters if extreme physics constraints in the physical world outpace their execution.

Persistent jet fuel spikes from the Gulf war obliterate operating margins.
Pilot shortages and unionization cap NOP flight volume.
The 'TrumpRx' deflationary regime forces a mandatory 30% cut to OCS reimbursement codes, destroying their compounding loop.

Current crowd narrative

The crowd currently views TransMedics as a successful but cyclical mid-cap MedTech stock that ran up fast and is now vulnerable to margin compression. The consensus trade is deeply anchored to legacy P/E methodologies and macro panic regarding energy costs and healthcare pricing. Wall Street research categorizes them simply as 'medical equipment', completely failing to underwrite the aviation-logistics monopoly that fundamentally changes their S-curve trajectory. They see a stock that had a great 2025 and assume the growth ceiling is hit.

Alpha-gap assessment

The variant perception is profound: TMDX is trading at a trailing P/E of ~15 with a 40% ROE and 37% YoY revenue growth. This is a mathematically irrational mispricing. The market is pricing TMDX as a mature, low-growth legacy manufacturer when first-principles physics dictates they are a true Paradigm Shifter. The blind spot is the failure to realize that the National OCS Program is a vertically integrated infrastructure play. You are buying the AWS of human biological logistics at deep-value multiples. The Alpha Gap is the chasm between their compounding FCF generation and the market's generalized macro fear.

Convergence catalyst

The catalyst will be the Q3/Q4 2026 earnings reports demonstrating that TMDX successfully maintained its +17% despite the Hormuz aviation fuel shock. When the market sees they possess absolute to pass through energy costs while accelerating unit volume, the 15 P/E multiple will aggressively re-rate to 35-40.

Macro-regime alignment

The Warsh-led higher-for-longer rate regime is a brutal headwind for companies dependent on external capital. However, it is an incredible tailwind for TMDX. They have already achieved escape velocity with $151M in TTM FCF and $3B market cap. They self-fund. The macro regime acts as a moat, suffocating potential capital-intensive competitors while TMDX aggressively harvests cash.

Paywalled preview begins: Macro-regime alignment

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Sentiment and regime

Greed and fear sentiment: -0.7
Expected volatility regime: high_erratic
Convergence-cycle position: growing_awareness

Primary drivers

Primary drivers supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
WARM Perfusion Paradigm Shift	Evaluate the physics: putting a human heart in a plastic cooler full of ice is a barbaric, thermodynamically foolish legacy paradigm. TransMedics’ Organ Care System (OCS) keeps organs alive, breathing, and pumping warm blood. This is a 10x fundamental improvement over cold static storage. By operating at the limits of biological necessity rather than hospital convenience, TMDX fundamentally restructures the transplant survival curve. This first-principles superiority is driving a non-linear S-curve adoption phase, permanently destroying the ice-cooler market.	Not available%	+65.0%
NOP Aviation Logistics Monopoly	TMDX didn't just build the hardware; they vertically integrated the entire logistical stack by acquiring an aviation fleet (National OCS Program). They control the atoms (planes, surgeons, physical organs) and the bits (algorithmic routing). Wall Street values them as a medical device company, completely missing that they are building the 'AWS of biological transport'. By owning the infrastructure layer, they dictate the market and create an insurmountable moat against incremental optimizers.	Not available%	+50.0%
Escape Velocity CASH Generation	The math is undeniable. TMDX achieved escape velocity. They transitioned from burning heavy capital (-$192M FCF in 2023) to build their aviation fleet, to massive cash generation (+$134M FCF and +$190M Net Income in 2025). The capital expenditure phase is in the rear-view mirror. They are now an autonomous, self-funding compounding machine immune to the Warsh-era liquidity drain and higher-for-longer rates.	Not available%	+40.0%
DCD Organ POOL Expansion	The true visionary TAM is not today's utilized organs; it is the massive pool of discarded and DCD (Donation after Circulatory Death) organs previously deemed unviable. OCS technology physically resuscitates and assesses these organs in transit. This expands the global supply of usable hearts, livers, and lungs exponentially, fundamentally altering the total addressable market of end-stage organ failure. This is TAM creation, not just TAM capture.	Not available%	+35.0%

Primary frictions

Primary frictions supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Aviation FUEL & Energy Shocks	The Hormuz blockade and extreme global energy shocks act as a severe thermodynamic tax on TMDX's National OCS Program. Jet fuel is the primary physical input cost for scaling a nationwide aviation fleet. When Brent crude spikes wildly, the operational margins of moving organs via jet aircraft compress. While the end-product is highly inelastic (a dying patient needs the organ), near-term margin erosion is mathematically inevitable under 2026 Middle East energy volatility.	Not available%	-20.0%
Physical Scaling Bottlenecks	You cannot software-update an airplane. TMDX is bound by hard physical constraints: pilot shortages, aircraft maintenance intervals, and hangar space. Scaling a dedicated Part 135 aviation network introduces brutal physical-world friction. As they expand, the execution velocity is rate-limited by FAA regulations and the raw logistics of keeping complex mechanical assets in the air 24/7/365. This restricts their S-curve acceleration.	Not available%	-15.0%
Healthcare Deflationary Mandates	The current US administration's 'TrumpRx' and healthcare cost-crushing initiatives pose a direct systemic risk to high-margin MedTech. While TMDX provides immense systemic value by reducing post-operative ICU days, governments and insurers under severe fiscal stress will inevitably try to cap reimbursement rates for the OCS hardware and NOP transport fees. This creates a perpetual headwind against pricing power.	Not available%	-10.0%
Biosecure Supply Chain Friction	The fragmentation of the global order forces a localized reshoring of the electronics and specialized plastics required for the OCS single-use consumable sets. While TMDX is US-based, decoupling from Chinese contract manufacturing introduces a transition tax on their gross margins. The cost of recreating precision medical manufacturing in a high-inflation, tariff-heavy environment will act as a structural drag on cost-of-goods-sold.	Not available%	-5.0%

Tail opportunities

Tail opportunities supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Xenotransplantation Logistics BASE	As bio-engineered animal organs (xenotransplantation) move from science fiction to clinical reality, they will require massive, centralized biological foundries. TMDX is perfectly positioned to serve as the exclusive transport and preservation layer for this new paradigm. Securing exclusive logistics contracts with top gene-editing oncology/transplant pioneers would double their future TAM overnight.	25.0%	+60.0%
AI Predictive Viability Monopoly	Frontier-Tech Disruption Test: If TMDX integrates deep-learning models to analyze real-time metabolic data flowing from the OCS during transit, they transition from an 'adaptive survivor' to an AI pioneer in organ diagnostics. A breakthrough where TMDX algorithms become the FDA-mandated standard for predicting transplant success would instantly software-lock the entire global transplant network to their platform.	35.0%	+45.0%

Tail risks

Tail risks supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Localized BIO Printing Obsolescence	Strip away the present and look 50 years out. The ultimate existential threat to TMDX is the perfection of in-hospital 3D bio-printing of autologous organs using the patient's own stem cells. If you can print a heart at the point of care, the entire physical necessity of transporting organs across the country at Mach 0.8 is erased. It is a legacy casualty risk.	10.0%	-80.0%
Catastrophic Fleet Grounding	Operating a hyper-active aviation network carries binary risk. A catastrophic safety event involving a NOP aircraft leading to an FAA fleet-wide grounding would instantly paralyze their vertical integration strategy, reverting them to reliance on inefficient commercial logistics and destroying their primary operational moat.	15.0%	-40.0%

Step-by-step forecast path

Elon Musk forecast path for prediction task predrqst_batch_task__xrefsubjtskconf_273d72b6-dd34-5604-9892-0228fd7b97c0__sb5__20260605080350
Step	Forecast date	Step change	Projected value (USD)	Scenario rationale
1	September 4, 2026	+18.0%	84.22	Initial multiple expansion. The market digests that a 15 P/E is utterly absurd for a monopoly generating 40% ROE and +134M FCF, shrugging off the immediate Hormuz fuel-cost panic as they demonstrate unyielding pricing power.
2	December 4, 2026	+12.0%	94.32	S-curve acceleration continues. End-of-year financials confirm OCS is rapidly becoming the mandated standard of care, completely displacing cold static storage across major US transplant hubs.
3	March 4, 2027	-6.0%	88.66	Temporary macroeconomic drag. Sticky inflation and higher-for-longer rates trigger broad market deleveraging, and TMDX absorbs collateral damage despite pristine fundamentals.
4	June 4, 2027	+9.0%	96.64	Recovery and margin validation. The physical constraints of the NOP aviation fleet are mitigated by strategic efficiency gains and algorithmic routing improvements, restoring operating leverage.
5	September 4, 2027	+14.0%	110.17	International momentum builds. Regulatory approvals in European and Asian markets unlock the next TAM expansion vector, validating the global scalability of the perfusion paradigm.
6	December 4, 2027	+15.0%	126.70	Explosive fundamental compounding. DCD organ utilization metrics show a permanent shift in the transplant landscape. The market cap re-rates as TMDX is recognized as vital global health infrastructure.
7	March 4, 2028	+8.0%	136.83	Steady execution. Cash flows are deployed into strategic software and diagnostic acquisitions, pushing the company from a hardware/logistics provider into an AI-driven data monopoly.
8	June 4, 2028	+5.0%	143.68	Consolidation phase. Market pauses to evaluate the integration of new tech acquisitions and the ongoing maintenance Capex required for the aging initial aviation fleet.
9	September 4, 2028	-8.0%	132.18	Regulatory headline friction. Political scrutiny over aggregate healthcare costs and transport monopolies temporarily spooks institutional capital, driving a localized sell-off.
10	December 4, 2028	+11.0%	146.72	Rebound on invincible unit economics. Q3 earnings prove that despite regulatory noise, the life-saving nature of the technology makes demand perfectly inelastic. Earnings beat.
11	March 4, 2029	+12.0%	164.33	Frontier-tech validation. Early pilot programs acting as the logistics backbone for early-stage xenotransplantation trials succeed, effectively doubling the 10-year TAM outlook.
12	June 4, 2029	+7.0%	175.83	Compounding growth. The NOP fleet reaches maximum density in North America, resulting in optimized flight times, lower per-organ transit costs, and maximized gross margins.
13	September 4, 2029	+9.0%	191.66	Capital return acceleration. With the core infrastructure fully built out, TMDX initiates aggressive stock buybacks with its massive FCF, mathematically forcing the share price higher.
14	December 4, 2029	+6.0%	203.16	Maturation of the US market. Growth shifts from rapid US market-share capture to international expansion and diagnostic software upselling. A stable, high-margin quarter.
15	March 4, 2030	+10.0%	223.47	Major international milestone. The EU fully adopts warm perfusion as the mandatory standard of care, officially rendering cold-storage obsolete in Western medicine.
16	June 4, 2030	-5.0%	212.30	Valuation reality check. The stock experiences multiple-compression as it transitions from a hyper-growth disrupter into a mature, massive-cap infrastructure staple.
17	September 4, 2030	+8.0%	229.28	Resumption of trend. Broad macro liquidity cycles favor high-FCF monopolies. TMDX flexes pricing power on its hardware consumables to offset any remaining inflation vectors.
18	December 4, 2030	+10.0%	252.21	Xenotransplantation commercialization scaling. TMDX begins capturing significant revenue from dedicated non-human organ logistics lines, confirming the next massive S-curve.
19	March 4, 2031	+6.0%	267.34	Steady state dominance. TMDX is now effectively a public utility for human biology. Competitors have been starved of oxygen by the immense capital moat of the NOP.
20	June 4, 2031	+8.0%	288.73	The paradigm is complete. TransMedics sits alone at the apex of biological transport and diagnostics. The initial vision is realized, generating billions in terminal-state cash flow.

Advisor and configuration

Advisor: elon_musk__the_visionary__google_gemini_3_1_pro__20260201_preview_release
Persona: Elon Musk
Archetype: The Visionary
Model: (February 01, 2026) Preview Release
Provider: Google
Mode: THINKER with High Reasoning and Standard Creativity
Task configuration: elon_musk__the_visionary__google_gemini_3_1_pro__20260201_preview_release__equity__json__extnd_invest_thesis_4q_alphassym__ts_num_desc__h5y_s3m__var1__thinker__standard_creativity_high_thinking__batch
Forecast horizon: 5 year
Forecast steps: 20 steps of 3 month
Assembly type: Balanced Assembly
Assembly name: elon_musk__the_visionary__google_gemini_3_1_pro__20260201_preview_release THINKER Forecast Assembly
Input format: inmemory_base_placeholders__latest_eod_close_price_with_stats_and_fundamentals__var1
Output format: Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

Read the complete Elon Musk advisor methodology

Configuration components

aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa (subject_context)
aiassmprmtcmpnt_efec62e4-24c0-556a-8070-775c69b97643 (global_context)
aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa (subject_context)
aiassmprmtcmpnt_8115cc2a-d418-54b1-a616-49dfa91195f4 (task_guidelines)

Back to advisor navigation

End of the paywalled preview

The excerpt from Macro-regime alignment to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Other AI Advisor reports — limited previews

Elon Musk — RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity

Gemini 3.1 Pro

Limited structural preview, provided as simplified HTML. The complete report contains substantially more research: its investment thesis; bull and bear scenarios; macro-regime analysis; drivers, risks and opportunities; quarterly forecast tables and rationale; references and published configuration. Those findings and datasets are not included here. Sign in with the required subscription to open this advisor's full report.